Title: Effect of rosiglitazone on protein expression of cardiac adiponectin and its receptor type 1 in rats with type 2 diabetes
Abstract:Objective To investigate the effects of rosiglitazone on the expression of cardiac adiponectin and its receptor type 1 in type 2 diabetic rats, and explore the protective effect and its mechanisms of ...Objective To investigate the effects of rosiglitazone on the expression of cardiac adiponectin and its receptor type 1 in type 2 diabetic rats, and explore the protective effect and its mechanisms of rosiglitazone on diabetic cardiomyopathy. Methods Thirty-six male Wistar rats were randomly divided into control group, diabetic group and rosiglitazone group. Type 2 diabetes rat model was reproduced by feeding a high-fat, high-sugar diet followed by an intraperitoneal injection of a low dose of streptozotocin (STZ). Rats in rosiglitazone group were laraged with rosiglitazone 3mg/(kg·d), while in control group and diabetic group received same amount of normal saline for 3 months. After 3 months, rats were sacrificed, the heart of each rat was weighed and HW/BW was calculated. Cardiac protein expression of adiponectin receptor 1 (AdipoR1), AMP-activated protein kinase α (AMPK-α), phosphorylation of AMP-activated protein kinase α-subunits and glucose transporter 4 (GLUT4) were determined by Western blotting. Plasma and myocardial adiponectin levels were assayed by enzyme immunoassay. The maximum descent speed (-dp/dtmax) in the left ventricle isovolumetric relaxation period was measured by carotid artery intubation. Results After 3 months, HW/BW was elevated, while plasma and myocardial adiponectin levels, the protein expression of AdipoR1, phosphorylation of AMPK-α and GLUT4 were significantly decreased in diabetic group compared with that in control group (P0.05). Compared with that in diabetic group, HW/BW declined, while plasma and myocardial adiponectin levels, protein expression of AdipoR1, phosphorylation of AMPK-α and GLUT4 in rosiglitazone group had significantly increased (P0.05). The heart function in both diabetic and rosiglitazone group was significantly decreased compared with that in control group. -dp/dtmax in the left ventricle isovolumic relaxation period was 5250mmHg/s or less. The heart function was obviously improved in rosiglitazone group compared with that in diabetic group but still lower compared with that in control group. Conclusions The levels of myocardial adiponectin and its receptor 1 decline in type 2 diabetic rats. Rosiglitazone can up-regulate the levels of myocardial adiponectin and its receptor 1 and promote myocardial glucose oxidation, thus it can improve the heart function of diabetic rats.Read More
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot